Evidence map›Paper›PMID 36063222›Full record

ArticleJournal of cancer research and clinical oncology2023

Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma.

Nasrin Shayanfar, Ali Zare-Mirzaie, Mahsa Mohammadpour, Ensieh Jafari, Amirhosein Mehrtash, Nikoo Emtiazi, Fatemeh Tajik

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Clinical significance of CD166 and HER-2 in different types of gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Nasrin ShayanfarDepartment of Pathology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Ali Zare-MirzaieDepartment of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Mahsa MohammadpourDepartment of Medical School, Tehran University of Medical Sciences, Tehran, Iran.
Ensieh JafariDepartment of Biology, Faculty of Basic Science, Noor Danesh University, Isfahan, Iran.
Amirhosein MehrtashMolecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Nikoo EmtiaziDepartment of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Nikooemtiazi9@gmail.com.
Fatemeh TajikOncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran. efateme_tajik@yahoo.com.
Iran University of Medical Sciences · IRPasteur Institute of Iran · IRShahab Danesh University · IRTehran University of Medical Sciences · IR

Funding

Iran University of Medical Sciences Grant Number# 19921
6 · The paper itself

Abstract

introductionRecent developments in genomic sequencing have led to the identification of somatic mutations in isocitrate dehydrogenase 1 (IDH1) in various malignancies. IDH1 R132H is the most common mutation of IDH1, which affects codon 132 and results in the conversion of amino acid residue arginine (R) to histidine (H). This study is designed to evaluate the association between the expression of IDH1 R132H and clinicopathological characteristics in laryngeal squamous cell carcinoma (LSCC).

methodsThe expression pattern and clinical significance of IDH1 R132H were investigated in tissue microarrays (TMAs) of 50 LSCC tumors as well as adjacent normal tissues using immunohistochemistry. Then the exons of the 12 tumor samples with negative/weak positive staining were sequenced by applying polymerase chain reaction (PCR).

resultsThe results demonstrated that the cytoplasmic expression of IDH1 R132H was downregulated in tumor cells compared to adjacent normal tissues. A statistically significant association was found between a low level of cytoplasmic expression of IDH1 R132H protein and an increase in histological grade (p < 0.001), perineural invasion (p = 0.019), and lymph node involvement (p < 0.001). The exon4 sequencing results showed that only one sample was positive for IDH1 R132H mutation. IDH1 R132H expression was observed in 39 (78.0%) LSCC samples.

conclusionThese findings indicate that low cytoplasmic expression of IDH1 R132H may have clinical significance in LSCC patients and is associated with more aggressive tumor behavior and progression of the disease, which can help improve potential treatment in patients with LSCC. Further investigations are needed to understand the biological function of IDH1 R132H and larger sample size to confirm our findings.

Indexed as

Brain NeoplasmsGliomaHead and Neck NeoplasmsHumansIsocitrate DehydrogenaseMutationSquamous Cell Carcinoma of Head and NeckIDH1 protein, humanIsocitrate DehydrogenaseImmunohistochemistry (IHC)Isocitrate dehydrogenase 1 (IDH1)Laryngeal squamous cell carcinoma (LSCC)Polymerase chain reaction (PCR)Tissue microarray (TMA)

Identifiers

PMID36063222
PMCPMC11797294
OpenAlexW4294669820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.